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Photobiomodulation (PBM) therapy is a promising therapeutic approach for several
pathologies, including stroke. The biological effects of PBM for the treatment of cerebral
ischemia have previously been explored as a neuroprotective strategy using different
light sources, wavelengths, and incident light powers. However, the capability of PBM
as a novel alternative therapy to stimulate the recovery of the injured neuronal tissue
after ischemic stroke has been poorly explored. The aim of this study was to investigate
the low-level light irradiation therapy by using Light Emitting Diodes (LEDs) as potential
therapeutic strategy for stroke. The LED photobiomodulation (continuous wave, 830 nm,
0.2–0.6 J/cm2) was firstly evaluated at different energy densities in C17.2 immortalized
mouse neural progenitor cell lines, in order to observe if this treatment had any effect on
cells, in terms of proliferation and viability. Then, the PBM-LED effect (continuous wave,
830 nm, 0.28 J/cm2 at brain cortex) on long-term recovery (12 weeks) was analyzed in
ischemic animal model by means lesion reduction, behavioral deficits, and functional
magnetic resonance imaging (fMRI). Analysis of cellular proliferation after PBM was
significantly increased (1 mW) in all different exposure times used; however, this effect
could not be replicated in vivo experimental conditions, as PBM did not show an infarct
reduction or functional recovery. Despite the promising therapeutic effect described for
PBM, further preclinical studies are necessary to optimize the therapeutic window of this
novel therapy, in terms of the mechanism associated to neurorecovery and to reduce the
risk of failure in futures clinical trials.
Keywords: functional recovery, ischemic stroke, photobiomodulation therapy, magnetic resonance imaging,
animal model, intracerebral hemorrhage
INTRODUCTION
Photobiomodulation therapy has been investigated in the past few years as an alternative
treatment for stroke and traumatic brain injury (TBI) in order to promote a neuroprotective
effect and tissue regeneration (1–5). The main benefits attributed to brain PBM therapy are
related to different biological processes such as increasing cerebral metabolic function, stimulating
neurogenesis and synaptogenesis, and neuroprotection via anti-inflammatory, and antioxidant
biological signaling (5, 6).
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In the field of stroke, PBM applied in the acute phase has
been suggested as a promising therapeutic approach for inducing
functional recovery. Thus, some studies have demonstrated
that 808–660 nm Low Level Laser Therapy (LLLT) applied
after ischemia on experimental animals improved neurological
rating scores without increasing body temperature, by direct
illumination of the skin on shaved animals (7–10).
On the other hand, it has been shown that transcranial laser
therapy within 24 h from stroke onset is a safe procedure, in
terms of mortality or occurrence of adverse effects, when it is
used on stroke patients (11, 12). LLLT used alone or combined
with the thrombolytic treatment for stroke (recombinant tissue
plasminogen activator) did not increase the risk of hemorrhagic
transformation (13). Despite experimental evidences and human
safety, a clinical trial designed to analyze the beneficial effect near-
infrared laser therapy in stroke has showed negative results, in
part because many of the parameters used (therapeutic time-
window, laser intensity) were not sufficiently optimized for use
in animal preclinical studies (14).
Light emitting diodes (LEDs) devices have emerged as an
innovative source of brain PBM for a wide range of neurological
conditions, and their use has been approved by the US Food
and Drugs Administration. Different studies about LED-PBM
have been mainly tested on cell in vitro assays (15–18), or
in experimental animal studies like retinal alterations (19, 20),
and its use in neuronal injures have been even tested in
pathologies as TBI and stroke as a neuroprotectant approach,
with contradictory results (5, 9, 21).
In this regard, the biological effects of PBM for the treatment
of stroke have been widely explored using different light sources,
wavelengths, and incident powers in preclinical studies. However,
studies were mainly focused on the neuroprotective effects, while
neurorecovery processes were evaluated only by functional tests
or mortality rate, and the direct effect of PBM on recovery of
the damage neuronal tissue was not accurately tested so far.
In the field of magnetic resonance imaging (MRI), the interest
in functional magnetic resonance imaging (fMRI) has been
increasing significantly as a noninvasive tool to evaluate neural
activity and the efficacy of neurorecovery therapies (22).
Therefore, to evaluate if LED-PBM could induce any positive
effects of on neuronal recovery after stroke, in this study we have
studied first the effect of PBM at different energy densities in
cell culture, in terms of proliferation and viability. Secondly, we
have studied the long-term recovery effect of LED-PBM in an
animal model of transient ischemic stroke by means of reduction
of ischemic lesion size, and finally we have tested for the first time
functional recovery determined by fMRI in combination with
functional behavioral tests.
MATERIALS AND METHODS
Cellular in vitro Analysis of LED
Photobiomodulation
It is well-known that neuronal growth and proliferation is one
of the most relevant physiological mechanisms involved in the
beneficial effects of light (1, 3). In this study, we have performed
a previous in vitro evaluation about the effect of LED-PBM at
different energy densities on cellular proliferation and viability.
For that purpose, C17.2 immortalized mouse neural
progenitor cell line was used. C17.2 cells, provided by Prof.
Mathias Hoehn (Max-Planck Institute, Cologne, Germany),
were cultured in DMEM (78%), fetal bovine serum (10%), horse
serum (5%), penicillin-streptomycin (1%) (Gibco Invitrogen,
Paisley, UK), and amphotericin-B (1%) (Sigma-Aldrich, St.
Louis, MO, USA).
To analyze the effect of LED-PBM on cells, an 830 nm LED
array lamp (Quantum Spectralife 830 nm LED, QuantumDevices
Inc., WI, USA) was used as light source. C17.2 cells were seeded
(100,000 cells/well) in 6-well plates and placed at 15 cm from
the LED source for PBM. Based on previous studies (15–17),
light exposure was applied 2 consecutive days at 1, 5, and
10 mW during 6, 12, or 18min, obtaining energy intensities
from 0.2 to 6 J/cm2 (Supplementary Table 1). Non-exposed cells
(control) were maintained under the same conditions as the
18min exposed cells but without light stimulation.
To determine the influence of the PBM on the cellular
proliferation, total cell count was performed with trypan blue
staining (STEMCELL Technologies, Grenoble, France) and a
Neubauer counting chamber (Blaubrand, Sigma-Aldrich, St.
Louis, MO, USA) 24 h after the last PBM. Samples were diluted
1:5 with phosphate buffered saline (PBS) and 1:2 with Trypan
blue. Cell count was performed by using an inverted microscope
(Olympus IX51, Shinjuku, Tokyo, Japan).
For assessing the viability of the cells after PBM, supernatants
were collected from well culture, including a negative control
of lysed cells. Cell viability was determined by means of the
lactate dehydrogenase assay (LDH) (Lactate Dehydrogenase
Assay Kit. Sigma-Aldrich, St. Louis, MO, USA), following the
manufacturer’s protocol. In brief, supernatants were centrifuged
at 1,000 rpm for 5min and further incubated with LDH reagents
for 20min. Next, the plate was read in Synergy2 (Biotek
Instruments, Vermont, USA) at 490 nm and the viability rate was
calculated with respect to control and lysed values.
Animals Studies
All experimental protocols involving the use of research
animals have been approved by the University of Santiago de
Compostela (Spain) ethics committee (ref: 15010/2019/004) and
were performed according to the guidelines of the Animal
Welfare Committee of the host institution and in accordance
with applicable legislation of the European Union (86/609/EEC,
2003/65/EC, 2010/63/EU, RD 1201/2005 and RD 53/2013) and
following the ARRIVE Guidelines for animal experiments.
Male Sprague–Dawley rats (Harlan Laboratories, Barcelona,
Spain) weighing 300 ± 30 g (12 weeks old) were used in this
study. Animals were kept in a controlled environment at 22 ±
1◦C and 60 ± 5% humidity, with 12/12 h light/darkness cycles.
Animals were fed ad libitum with standard diet pellets and tap
water. All animals were housed individually.
All surgical procedures and MRI studies were conducted
under sevoflurane (Abbott Laboratories, IL, USA) anesthesia
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(3–4%) using a carrier 65:35 gas mixture of N2O:O2. For
fMRI experiments, animals were sedated with subcutaneous
administration of medetomidine (Domitor R©) (0.05 mg/kg bolus
and 0.1 mg/kg/h infusion) during fMRI data acquisition.
Respiration rate was continuously recorded non-invasively, and
body temperature was kept constant by a feedback-controlled
heating pad. After the experiment, sedation was antagonized
with an intraperitoneal injection of atipamezole (0.1 mg/kg). No
animal died during the follow-up period.
Surgical Procedures for Transient Focal
Ischemia
Transient middle cerebral artery occlusion (tMCAO) (60min of
occlusion) was induced by intraluminal occlusion of the middle
cerebral artery with silicon handmade sutures (head diameter
300–350µm), following the procedure described elsewhere (23,
24). A laser-Doppler flow probe (tip diameter 1mm) attached to
a flow meter (PeriFlux 5000; PerimedAB, Stockholm, Sweden)
was placed on the thinned skull (area = 0.8 mm2, thickness
= 0.2mm) over the MCA territory (4mm lateral to Bregma)
to continuously record the relative cerebral blood flow (CBF)
during the occlusion. Only animals with a reduction of CBF
higher than 60%, and with effective reperfusion after retrieving
the filament, were included in the study.
Light Penetration Into the Rat Brain
Before testing the effect of LED-PBM on ischemic animal
models, the penetration rate of light through different rat brain
tissues (rodent skin, skull, and brain) was performed. For this
purpose, the LED array lamp previously used in cellular studies
was employed (830 nm, 10 mW/cm2). To determine the light
penetration, a Newport 835 Laser Pico-Watt Digital PowerMeter
with 818 UV detector (Newport Corporation, Franklin, MA,
USA) was used.
Light penetration through tissues was measured with isolated
rat samples of skin, skull, and brain tissues. To evaluate the
influence of the power in the penetration of light through
different tissue samples, the LED lamp was located 15 cm
away from the sample. To perform this analysis, a sample
holder was made from black Plexiglas R©, and consists of a
base with an 8mm hole in its center where we placed the
samples and 3 black Plexiglas R© walls. Two photodetectors let the
simultaneous measurement of light power transmitted through
the different tissues we placed on the holder, and a portion of the
incident light.
Light penetration was calculated and performed 3 times (n =
2 animals). Data were processed using a program designed for
that purpose in C++ (Borland, Texas, USA). First, we measured
the power without any sample between the light source and the
detector (light in mW/cm2 across of air) and then we calculated
the percentage of transmitted light when samples were placed
on the system (light in mW/cm2 across of tissue). Relative
penetration percentage values were calculated using the following
formula obtained from a previous study (25):
100 % X
(









In vivo LED Photobiomodulation
Neurorecovery Analysis
Because TBI represents the type of neurological damage closest to
ischemic injury, we used similar continues LED PBM protocol in
our ischemic animal model (5). In our case, in order to reduce
as much as possible the stressful effects that LED-PBM could
induce on the experimental animals and interfere in the fMRI
experiments (26), we decided to test two different continuous
LED-PBM protocols; Group 1: 30min of light treatment, 1
day/week during 12 weeks (n = 6), and Group 2: 30min of
light treatment, 3 days/week during 12 weeks (n = 6). An
additional ischemic group without treatment was used as control
Group (n = 6). Animals were randomly assigned to the three
experimental groups. LED-PBMwas initiated 24 h after the onset
of ischemia in awake and freely moving conditions. Head animals
were shaved before light stimulation and the light exposure was
performed individually.
Based on the cellular in vitro experiments and light
penetration analysis on cerebral tissues, LED-PBM was induced
with a power density of 10 mW/cm2 to 1 cm2 of area (at 15 cm of
the source) with a light intensity of 18 J/cm2.
Magnetic Resonance Imaging
Magnetic Resonance Imaging and fMRI studies were conducted
on a 9.4 T horizontal bore magnet (BrukerBioSpin, Ettlingen,
Germany) with 20 cm wide actively shielded gradient coils (440
mT/m). MR images were acquired using a cross-coil setup,
consisting of a linear birdcage resonator of 7 cm diameter,
for transmission, and a 2 × 2 arrayed surface coil for
signal detection.
Infarct volume was determined by means of T2-weighted
images acquired at 24 h (defined as 0) and 1, 3, 5, 7, and 12 weeks
after the onset of ischemia using a multi-slice multi-spin-echo
(MSME) sequence with the following acquisition parameters:
repetition time (TR)= 3 s, 16 echoes with echo time (TE)= 9ms,
75KHz spectral bandwidth, flip angle (FA) = 180◦, 14 slices of
1mm thickness, field of view (FOV) of 19.2 × 19.2 mm2 (with
saturation bands to suppress signal outside this FOV), a matrix
size of 192× 192 (isotropic in-plane resolution of 0.1 mm/pixel),
and implemented without fat suppression option.
All images were processed using the ImageJ software
(Rasband, W.S., ImageJ, NIH) on an independent computer
workstation. Infarct volumes were quantified from T2-weighted
images averaged all echoes by a researcher blinded to the
treatment groups.
BOLD fMRI Methodology
Functional MRI was achieved using BOLD contrast, starting at
least 1 h after the induction of the sedation. fMRI experiments
were performed 1 week before tMCAO and 0 (24 h), 1, 3,
5, 7, and 12 weeks after ischemia, acquiring sets of 115
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consecutive spin-echo Echo-Planar-Images (SE-EPI) with TE/TR
= 30/3,000ms, 5 slices of 2mm thickness, FOV of 19.2 × 19.2
mm2 covered by a 64 × 64 matrix, i.e., an in-plane resolution
of 0.3 mm/pixel. Home-built steel needle (30G) electrodes were
placed subcutaneously into both forepaws. Alternating unilateral
forepaw stimulation was performed using rectangular pulses
(2mA, 8Hz, 0.3ms, STG2004 stimulator from Multi Channel
Systems, Germany) following a paradigm in which a block,
composed by a 45 s resting period and 15 s activation period,
was repeated five times, ending with an additional 45 s resting
period for a total experimental time of 5min 45 s (5 × [45
OFF + 15 ON] + 45 OFF). BOLD fMRI technique is based on
the differential magnetic properties of oxygenated (diamagnetic)
and deoxygenated (paramagnetic) hemoglobin. Upon neural
activation, changes in local CBF, cerebral blood volume (CBV),
and cerebral metabolic rate of oxygen consumption (CMRO2)
leads to a locally increased ratio of oxygenated over deoxygenated
hemoglobin, resulting in an enhancement in T2∗-weighted signal
intensity (27).
BOLD fMRI was conducted, alternating three times
between each hemisphere, and animals were allowed
to rest for 10min between stimulation sessions. After
pre-processing, the BOLD signal was modeled as the
convolution of the applied stimulation design (block or
event-related design) with the hemodynamic response
function (HRF) in order to have a better estimation of
the true design-related BOLD signal. Finally, statistics was
performed on the model estimates defining brain regions
activated (27).
Statistical parametric activation maps were constructed with
the software STIMULATE (28). The time course of each
pixel during forepaw stimulation was examined using a paired
Student’s t-test (p < 0.05) according to previous studies (29,
30), comparing the mean baseline signal value with the mean
of the stimulated signal value. Only clusters that included at
least four adjacent activated pixels were considered as positive
activation areas.
Sensorimotor Test: Cylinder Test
A cylinder test (31) was used to evaluate the functional deficit
and was performed 1 week prior to tMCAO (to assess the basal
locomotor symmetry of the animals) and 24 h (defined as 0), 1,
3, 5, 7, and 12 weeks after ischemia during the darkness cycle
(Supplementary Material).
Brain Histological Analysis
Animals were sacrificed 12 weeks after surgical treatment, and
brain tissue was processed for histological analysis, following
the procedure described elsewhere (32). Neuronal nuclear
protein (Fox3) and glial fibrillary acidic protein (GFAP) (Sigma-
Aldrich) labeling were combined with DAPI stain (Thermo
Fisher Scientific, Waltham, MA, USA). In addition, neurogenesis
was examined in the striatal region by immunolabeling a
proliferating cell marker (Ki-67, Abcam) and doublecortin (DCX;
an immature progenitor cell marker) (Dako, Barcelona, Spain).
Doblecortin and Ki-67 positive, GFAP-positive and Fox3-positive
cells and nuclei were counted manually in ImageJ software
(Supplementary Material).
Statistical Analysis
All data are presented as the mean and standard deviation of
the mean (mean ± SD). The Kolmogorov-Smirnov test was
performed in order to check the normality of distributions.
Two-way analysis of variance (ANOVA) followed by post-hoc
Bonferroni evaluation was used for multiple groups to determine
significant differences. Statistical significance was set at p <
0.05. The statistical analysis was conducted using IBM SPSS
Statistics for Macintosh, Version 18.0. (SPSS Inc., IL, USA).
Statistical analysis was performed by a blinded researcher to the
treatment. Sample size was based on expected variances: α= 0.05
(confidence level: 95%) and β = 0.20 (power: 80%).
To achieve a power of 80% to detect differences in the contrast
of the hypothesis null H0 (LED-PBM treatment could reduce
the ischemic lesion by 30%) taking into account that the level of
FIGURE 1 | In vitro study to evaluate: (A) cellular proliferation; cell count was found significant increased at low emission powers and exposures times. (B) Viability;
photostimulaltion did not produce toxic side effects in vitro. A two-way analysis of variance (ANOVA) followed by post-hoc Bonferroni evaluation was used. (n = 4;
*p < 0.5; **p < 0.01; ***p < 0.001). Lamp emission power at three different exposure time (6, 12, and 18 min).
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significance is 5%, the number of animal in each group is n = 6.
The calculation has been made with the program Ene 3.0.
RESULTS
In vitro Analysis of Photobiomodulation
Analysis of cellular proliferation after PBM was significantly
increased with a density power of 1 mW in all different exposure
times tested, however higher intensities did not show higher
effects (Figure 1A). To determine if the PBMwas associated with
cellular death, LHD assay was performed (Figure 1B). Although
it did not achieve a significant difference, a higher cell death was
observed only in those cells treated for 18min with 5 mW of
light exposure. Based on these in vitro results, we established 0.2–
0.6 J/cm2 (Supplementary Table 1) as the optimal light energy
intensity needed to induce any beneficial effect on the neuronal
tissue in the in vivo animal study.
In vivo Photobiomodulation Effect on
Functional Recovery and Ischemic Lesion
A total number of 20 animals were used in the study: 2 animals
involved in the light penetration analysis into the brain, and 18
animals in the neurorecovery analysis. Two animals died during
the surgery, and 3 animals did not meet the inclusion criteria in
relation to the reduction of CBF.
Light penetration was determined through the different
tissues, resulting 16 ± 3% through the shaved skin, 10
± 3% through the skull, 0.9 ± 0.4% through right brain
hemisphere (ischemic), and 0.9 ± 0.4% through left brain
hemisphere (healthy).
Analysis of light penetration study through different biological
tissues from rat (rodent skin, skull, and brain) showed that the
decay of light intensity rate along the deep brain tissue resulted
about 2.5 × 10−2 J/cm2. Based on this analysis, light PBM
intensity was adjusted to 18 J/cm2 that allowed inducing on brain
cortex with a light intensity of 0.28 J/cm2, close to that values
established in the previous in vitro study (0.2–0.6 J/cm2).
Functional MRI was performed in all animals prior to
the tMCAo and all of them exhibited bilateral BOLD signal
(Figure 2). Nevertheless, 12 weeks after PBM treatment, animals
did not show the recovery BOLD signal in the ischemic
hemisphere with none of the protocols used. In line with fMRI
results, analysis of the profile of lateral index (that determinates
the forelimb asymmetry) analyzed during the period of follow up,
did not show a significant improvement in the functional deficit
in the treated groups respect to the control group (Figure 3A).
FIGURE 2 | Functional brain recovery observation. (A) Representative BOLD images obtained during pre-cerebral ischemia, 5 and 12 weeks after the insult in both
hemispheres. (B) Alternating unilateral forepaw stimulation was performed using rectangular pulses. BOLD fMRI was conducted alternating three times between each
hemisphere, and animals were allowed to rest for 10min between stimulation sessions. The time course of each pixel during forepaw stimulation was examined using
a paired Student’s t-test (p < 0.05). Only clusters that included at least four adjacent activated pixels were considered as positive activation areas. (n = 6
animals/group). All animals exhibited BOLD signal in both hemispheres (measured separately) prior to the cerebral ischemia. The animals were followed for 12 weeks
and all of them exhibited BOLD signal in the contralateral side but none of them showed BOLD activation in the ipsilateral side.
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FIGURE 3 | In vivo study: (A) Cylinder test results obtained from the three studied groups. (B) Ischemic volume results of the three groups; No significant differences
were observed between groups up to 12 weeks. (C) T2-weighted MR images of a representative brain of each photostimulated group.
Nonetheless, the treated groups showed a reduction of the use of
the impaired forelimb, but the difference did not reach statistical
significance compared to the control group.
Figure 3B detailed the evolution of the lesion sizes of ischemic
animals. All the animals included in the study presented a basal
ischemic lesion (<18%) determined by MRI. According to our
experimental design, a reduction of 30% in the ischemic lesion
was not found. In line with this, no significant differences in
volume reduction were observed for the groups compared to
control. Under these experimental conditions, analysis of infarct
volume showed that LED photostimulation doesn’t reduce the
ischemic lesion in the treated animals compared with the control
group (Figure 3C). Besides, subarachnoid hemorrhages were
found in all groups (control group included) due to the large
ischemic lesions induced with the tMCAOmodel.
Histological analysis of a neuronal marker (Fox3), glial marker
(GFAP), and neurogenesis performed 12 weeks after stroke onset
did not reveal expression differences in either immunolabeling
(Figure 4). All animals used were included in the study and no
mortality associated to PBM was observed.
DISCUSSION
In the present study, PBM with 830 nm LED at low energy
intensity (0.28 J/cm2) did not reduce the infarct volume or
improve the functional recovery 12 weeks after the onset of the
ischemia. The electrical activity and therefore fMRI signal in
response to the forepaw stimulation was observed exclusively in
the contralateral hemisphere, evidencing no functional recovery
after cerebral ischemia in the ipsilateral side. Other therapeutic
studies with very different treatments, as stem cells, but
where fMRI was used to evaluate the functional recovery after
ischemic stroke have evidenced that the regaining of BOLD
signal was produced between the 7th and the 10th week after
the administration (33). Therefore, and although the therapy
is completely different, we coinsured that 12 weeks were a
prudential period to see some effect of LED-PBM through fMRI.
Numerous studies have found positive effects conferred by
PBM from decreasing inflammation, alleviating oxidative stress,
and improving mitochondrial function (5–10). Some studies
have evidenced reduction of cerebral ischemic lesions, better
functional outcome or cell neurogenesis in different animal
models (8–10). However, in line with our results, these PBM
therapies were mainly applied within the first 6 h from stroke
onset, while no benefit was observed at longer time-points.
Similarly, the clinical Phase III (NEST-3) study about the
therapeutic effect of PBM that did not find significant benefit in
stroke patients (14).
In our study, 24 h after stroke was selected as the time-
point to start the LED-PBM treatment, in order to study repair-
based therapies complement acute therapies (intravenous or
intraarterial fibrinolysis, thrombectomy). Besides, within the first
24 h after stroke, patient requires clinical care,MRI, or Computed
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FIGURE 4 | Histological analysis of neurons (Fox3), astrocytes (GFAP), and neurogenesis (DCX and Ki 67) of animals from each experimental group at 12 weeks after
ischemic lesion. Cortical (*) and subcortical brain regions (**).
Tomography (CT) studies, which would limit the possibility of
implementing the PBM protocols.
We have evaluated the evolution of the ischemic brain by
using MRI and fMRI after in vivo PBM, however our study
also shows some weaknesses. First, the use of an ischemic
cell model [oxygen-glucose deprivation (OGD)] would help
understand basic biochemical and cellular mechanisms involved
in the effects of light. Second, it would be possible that prolonged
individual housing of animal prevented optimal recovery and
negatively impacted to detect a therapeutic effect. Third, a
deep histological analysis would contribute to elucidate the
light effects in the damaged brain at a cellular level, or even
to describe possible endogenous angiogenic or neurogenic
processes stimulated by the LED light. In addition, in this
study we have used a tMCAO model that induces large
ischemic lesion with a high sensorimotor cortex affectation,
that can limit the functional recovery as it has been reported
in other studies (33), and potentially explain the lack of PBM
effect observed in ours animals. Indeed, this could also reflect
that this treatment could be more appropriate for smaller
stroke lesions.
Hundreds of clinical trials testing protective agents have failed
despite efficacy in experimental models. In this line, from a long
time ago, negative and neutral studies have been required to help
move novel treatments to human and reduce the risk of failure
in futures clinical trials (34, 35). Therefore, these new findings
try to contribute to optimize the potential use PBM as novel
and non-invasive therapy for ischemic stroke before moving to
clinical studies.
CONCLUSION
Under our experimental conditions, we have not observed a
beneficial effect of LED photobiomodulation applied 24 h after
the onset of ischemia in animal models, mainly in terms of
neuronal recovery determined by fMRI. Further preclinical
studies in this field are necessary in order to optimize the
therapeutic window of this novel therapy, the mechanism
associated and to reduce the risk of failure in futures clinical trials.
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